Fascin-1 expression is associated with neuroendocrine prostate cancer and directly suppressed by androgen receptor.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
10
03
2022
accepted:
20
09
2023
revised:
11
08
2023
pubmed:
25
10
2023
medline:
25
10
2023
entrez:
24
10
2023
Statut:
ppublish
Résumé
Neuroendocrine prostate cancer (NEPC) is an aggressive form of prostate cancer, arising from resistance to androgen-deprivation therapies. However, the molecular mechanisms associated with NEPC development and invasiveness are still poorly understood. Here we investigated the expression and functional significance of Fascin-1 (FSCN1), a pro-metastasis actin-bundling protein associated with poor prognosis of several cancers, in neuroendocrine differentiation of prostate cancer. Differential expression analyses using Genome Expression Omnibus (GEO) database, clinical samples and cell lines were performed. Androgen or antagonist's cellular treatments and knockdown experiments were used to detect changes in cell morphology, molecular markers, migration properties and in vivo tumour growth. Chromatin immunoprecipitation-sequencing (ChIP-Seq) data and ChIP assays were analysed to decipher androgen receptor (AR) binding. We demonstrated that FSCN1 is upregulated during neuroendocrine differentiation of prostate cancer in vitro, leading to phenotypic changes and NEPC marker expression. In human prostate cancer samples, FSCN1 expression is restricted to NEPC tumours. We showed that the androgen-activated AR downregulates FSCN1 expression and works as a transcriptional repressor to directly suppress FSCN1 expression. AR antagonists alleviate this repression. In addition, FSCN1 silencing further impairs in vivo tumour growth. Collectively, our findings identify FSCN1 as an AR-repressed gene. Particularly, it is involved in NEPC aggressiveness. Our results provide the rationale for the future clinical development of FSCN1 inhibitors in NEPC patients.
Sections du résumé
BACKGROUND
BACKGROUND
Neuroendocrine prostate cancer (NEPC) is an aggressive form of prostate cancer, arising from resistance to androgen-deprivation therapies. However, the molecular mechanisms associated with NEPC development and invasiveness are still poorly understood. Here we investigated the expression and functional significance of Fascin-1 (FSCN1), a pro-metastasis actin-bundling protein associated with poor prognosis of several cancers, in neuroendocrine differentiation of prostate cancer.
METHODS
METHODS
Differential expression analyses using Genome Expression Omnibus (GEO) database, clinical samples and cell lines were performed. Androgen or antagonist's cellular treatments and knockdown experiments were used to detect changes in cell morphology, molecular markers, migration properties and in vivo tumour growth. Chromatin immunoprecipitation-sequencing (ChIP-Seq) data and ChIP assays were analysed to decipher androgen receptor (AR) binding.
RESULTS
RESULTS
We demonstrated that FSCN1 is upregulated during neuroendocrine differentiation of prostate cancer in vitro, leading to phenotypic changes and NEPC marker expression. In human prostate cancer samples, FSCN1 expression is restricted to NEPC tumours. We showed that the androgen-activated AR downregulates FSCN1 expression and works as a transcriptional repressor to directly suppress FSCN1 expression. AR antagonists alleviate this repression. In addition, FSCN1 silencing further impairs in vivo tumour growth.
CONCLUSION
CONCLUSIONS
Collectively, our findings identify FSCN1 as an AR-repressed gene. Particularly, it is involved in NEPC aggressiveness. Our results provide the rationale for the future clinical development of FSCN1 inhibitors in NEPC patients.
Identifiants
pubmed: 37875732
doi: 10.1038/s41416-023-02449-x
pii: 10.1038/s41416-023-02449-x
pmc: PMC10703930
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1903-1914Subventions
Organisme : Institut National Du Cancer (French National Cancer Institute)
ID : INCa_4419
Informations de copyright
© 2023. The Author(s).
Références
Lancet. 2016 Jan 2;387(10013):70-82
pubmed: 26074382
Nature. 2017 Jan 19;541(7637):359-364
pubmed: 28068672
Asian J Androl. 2019 May-Jun;21(3):241-248
pubmed: 29900883
Front Oncol. 2015 Apr 14;5:90
pubmed: 25927031
Asian J Androl. 2019 May-Jun;21(3):215-223
pubmed: 30950412
Curr Biol. 2010 Feb 23;20(4):339-45
pubmed: 20137952
Front Oncol. 2014 Mar 25;4:60
pubmed: 24724054
Nature. 2012 Jul 12;487(7406):239-43
pubmed: 22722839
J Natl Compr Canc Netw. 2014 May;12(5):719-26
pubmed: 24812138
Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):11139-44
pubmed: 25024180
Nat Rev Urol. 2018 May;15(5):271-286
pubmed: 29460922
Cancer Discov. 2017 Jul;7(7):736-749
pubmed: 28411207
Lancet Oncol. 2015 Sep;16(9):e435-e446
pubmed: 26370353
Endocr Relat Cancer. 2006 Mar;13(1):151-67
pubmed: 16601285
Prostate Suppl. 1996;6:3-8
pubmed: 8630226
Nat Med. 2016 Apr;22(4):369-78
pubmed: 26928463
Nat Rev Mol Cell Biol. 2011 Jun 23;12(7):413-26
pubmed: 21697900
Cells. 2019 Aug 09;8(8):
pubmed: 31405024
Nucleic Acids Res. 2002 Jan 1;30(1):207-10
pubmed: 11752295
J Clin Oncol. 2018 Aug 20;36(24):2492-2503
pubmed: 29985747
Cancer Cell. 2010 Jul 13;18(1):11-22
pubmed: 20579941
Cold Spring Harb Perspect Med. 2019 Feb 1;9(2):
pubmed: 29844220
Int J Cancer. 2023 Jul 1;153(1):210-223
pubmed: 36971100
Eur Urol. 2021 Feb;79(2):263-282
pubmed: 33039206
Eur Urol. 2015 Mar;67(3):470-9
pubmed: 25306226
Nat Rev Cancer. 2015 Dec;15(12):701-11
pubmed: 26563462
Cancer Lett. 2018 Dec 1;438:32-43
pubmed: 30201302
Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11428-11436
pubmed: 31061129
J Clin Oncol. 2012 Dec 20;30(36):e386-9
pubmed: 23169519
Br J Cancer. 2003 Feb 24;88(4):537-47
pubmed: 12592367
Commun Integr Biol. 2010 May;3(3):263-70
pubmed: 20714410
Int J Biochem Cell Biol. 2005 Sep;37(9):1787-804
pubmed: 16002322
Cancers (Basel). 2020 Apr 02;12(4):
pubmed: 32252342
Prostate. 2011 Nov;71(15):1668-79
pubmed: 21432867
Oncogene. 2014 Apr 24;33(17):2204-14
pubmed: 23708657
Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5
pubmed: 23193258
Eur Urol. 2018 Mar;73(3):322-339
pubmed: 28927585
Nat Commun. 2014 May 30;5:3972
pubmed: 24875621
Mol Biol Cell. 1998 May;9(5):993-1006
pubmed: 9571235
Cell. 2013 Apr 25;153(3):666-77
pubmed: 23622249
PLoS One. 2013 Sep 19;8(9):e75092
pubmed: 24069383
Mol Endocrinol. 2003 Aug;17(8):1484-507
pubmed: 12750453
Genome Res. 2002 Jun;12(6):996-1006
pubmed: 12045153
Nat Med. 2016 Mar;22(3):298-305
pubmed: 26855148
Curr Oncol Rep. 2021 Jan 12;23(2):15
pubmed: 33433737
Nat Genet. 2018 May;50(5):645-651
pubmed: 29610475
Eur Urol. 2021 Feb;79(2):243-262
pubmed: 33172724
Biomark Cancer. 2017 May 30;9:1179299X17710944
pubmed: 28607544
Clin Cancer Res. 2009 Feb 15;15(4):1376-83
pubmed: 19228738
Oncotarget. 2017 Feb 14;8(7):11827-11840
pubmed: 28055969
Cancer Discov. 2017 Jan;7(1):54-71
pubmed: 27784708
JCO Precis Oncol. 2017 Jul;2017:
pubmed: 28825054
Gastroenterology. 2014 May;146(5):1386-96.e1-17
pubmed: 24462734
Nat Commun. 2021 Mar 30;12(1):1979
pubmed: 33785741
PLoS One. 2013;8(1):e53701
pubmed: 23326489
Nat Med. 2017 Jun 6;23(6):1-10
pubmed: 28586335
J Cancer. 2022 May 9;13(8):2528-2539
pubmed: 35711849
Mol Cell. 2002 Mar;9(3):601-10
pubmed: 11931767
Cancer Cell. 2017 Oct 9;32(4):474-489.e6
pubmed: 29017058
Bioessays. 2002 Apr;24(4):350-61
pubmed: 11948621
Int J Urol. 2018 Apr;25(4):345-351
pubmed: 29396873
FEBS J. 2021 Mar;288(5):1434-1446
pubmed: 32657526
Nat Genet. 2012 May 20;44(6):685-9
pubmed: 22610119
Science. 2009 May 8;324(5928):787-90
pubmed: 19359544
J Urol. 1999 Nov;162(5):1800-5
pubmed: 10524938
Eur Urol. 2019 Jan;75(1):88-99
pubmed: 29673712
BMC Med. 2013 Feb 26;11:52
pubmed: 23442983